Roche announces new Corporate Executive Committee

08-Sep-2009 - Switzerland

Roche announced a new Corporate Executive Committee. At the end of 2009 William M. Burns (62), CEO Pharma Division, Juergen Schwiezer (65), CEO Diagnostics Division, and Jonathan Knowles (62), Head Group Research, will resign from the Corporate Executive Committee. Juergen Schwiezer and Jonathan Knowles will retire, while William M. Burns will be proposed as a Member of the Roche Board at the Annual Shareholder Meeting 2010.

William M. Burns started his career in 1986 with Roche UK. He has been a Member of the Corporate Executive Committee for ten years, thereof eight years as Head Pharma Division. Juergen Schwiezer joined Boehringer Mannheim in 1976 and was appointed Head of its Executive Committee in 1995. He became a Member of the Executive Committee Roche Germany in 1998 and was heading the Diagnostics Division as Member of the Roche Corporate Executive Committee since 2008. Prof. Jonathan Knowles was appointed Head Roche Research in 1997 and has been a Member of the Corporate Executive Committee since 1998.

The Board of Directors has made the following appointments, effective 1 January 2010:

Medix Biochemica acquires myPOLS Biotec

All founders of myPOLS Biotec will remain involved in the business following the acquisition

Read news

Pascal Soriot (50), currently CEO Genentech and Member of the Corporate Executive Committee, is appointed Chief Operating Officer (COO) Pharma Division and assumes global responsibility for Pharma operations. These include commercial operations worldwide, global marketing, production, development and registration.

Jean-Jacques Garaud (54), currently Head Pharma Development, is appointed Member of the Enlarged Executive Committee and assumes responsibility for Roche Pharma Research and Early Development.

Dan Zabrowski (50), Head Pharma Partnering, is also appointed Member of the Enlarged Executive Committee.

Richard Scheller is a Member of the Enlarged Executive Committee. Based in San Francisco, he is responsible for Genentech Research and Early Development, which is managed as an independent unit.

Jean-Jacques Garaud, Richard Scheller and Dan Zabrowski report to Severin Schwan.

Daniel O’Day (45), currently Head Roche Molecular Diagnostics, is appointed Chief Operating Officer (COO) Diagnostics Division and Member of the Executive Committee. Burkhard Piper, Head Roche Diabetes Care, reports to Daniel O’Day.

Ian Clark (49), currently Head Global Product Strategy Pharma, will succeed Pascal Soriot as CEO Genentech. He will report to Pascal Soriot and will be based in South San Francisco.

https://www.bionity.com/en/news/105987/roche-announces-new-corporate-executive-committee.html